FDA seeks treatment protocol for Protalix Gaucher's disease drug

07/6/2009 | Wall Street Journal, The

The FDA asked Protalix to submit a treatment protocol for prGCD, its experimental Gaucher's disease drug, in light of a manufacturing problem that is expected to reduce the supply of Genzyme's Cerezyme. Protalix and the agency are reportedly discussing parameters to increase patients' access to prGCD.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ